Research map: Nirsevimab Benefits Beyond the First Year After Birth

Back to the article

Papers in this map

  1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 · Rafael Lozano · 2012 · 14337 citations · Cited by this paper
  2. Trends in Pediatric Hospitalizations Following Interfacility Transfer: 2009–2022 · 2026 · Related
  3. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis · You Li · 2022 · 2024 citations · Cited by this paper
  4. Auricular Neurostimulation: A Novel Therapy for Abdominal Pain-Related Disorders of Gut-Brain Interaction · 2026 · Related
  5. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants · The IMpact-RSV Study Group · 1998 · 1987 citations · Cited by this paper
  6. Telemedicine Use in Primary Care for Children: 2019–2024 · 2026 · Related
  7. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus · Jason S. McLellan · 2013 · 1171 citations · Cited by this paper
  8. Hearing-Targeted Congenital Cytomegalovirus Screening: An 11-Year Experience · 2026 · Related
  9. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants · Laura L. Hammitt · 2022 · 1053 citations · Cited by this paper
  10. Building the Foundations for Trustworthy AI in Pediatrics · 2026 · Related
  11. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody · Jason S. McLellan · 2013 · 907 citations · Cited by this paper
  12. Blood Lead Testing Among Children Enrolled in Medicaid · 2026 · Related
  13. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 · Jefferson M. Jones · 2023 · 368 citations · Cited by this paper
  14. Transplant Center Variability and Its Role in US Pediatric Liver Care Inequities · 2026 · Related
  15. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study · Sonia Ares‐Gómez · 2024 · 259 citations · Cited by this paper
  16. A Resource to Understand and Prevent Sudden Unexpected Infant Deaths · 2026 · Related
  17. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 · Heidi L. Moline · 2024 · 224 citations · Cited by this paper
  18. Child Welfare System Involvement in the United States: 2016–2023 · 2026 · Related
  19. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study · Guillermo Ezpeleta · 2024 · 87 citations · Cited by this paper
  20. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access · Jonne Terstappen · 2024 · 86 citations · Cited by this paper
  21. Clesrovimab for Prevention of RSV Disease in Healthy Infants · Heather Joy Zar · 2025 · 81 citations · Cited by this paper
  22. Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study · Marta Agüera · 2024 · 36 citations · Cited by this paper
  23. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011–2019 · Mina Suh · 2022 · 33 citations · Cited by this paper
  24. Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study · Josefina Lorena Razzini · 2026 · 23 citations · Cited by this paper
  25. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement · Sean T. O’Leary · 2025 · 22 citations · Cited by this paper
  26. Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024 · Stephanie A. Irving · 2025 · 19 citations · Cited by this paper
  27. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives · Etienne Bizot · 2025 · 15 citations · Cited by this paper
  28. Impact of Viral Lower Respiratory Tract Infection (LRTI) in Early Childhood (0–2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health (NIH) Workshop Summary · Hitesh S. Deshmukh · 2024 · 12 citations · Cited by this paper
  29. Impact of nirsevimab immunoprophylaxis on respiratory syncytial virus-related outcomes in hospital and primary care after two consecutive seasons: a population-based retrospective cohort study in infants in their second year of life in Catalonia, Spain · Ermengol Coma · 2025 · 7 citations · Cited by this paper
  30. Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season · Isabel González‐Bertolín · 2025 · 6 citations · Cited by this paper
  31. Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis · Brody J. Lipsett · 2025 · 5 citations · Cited by this paper
  32. Barriers to Administering Maternal RSV Vaccination and Monoclonal Antibodies · Haya Hayek · 2025 · 3 citations · Cited by this paper
  33. Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab · Karen P. Acker · 2026 · 3 citations · Cited by this paper
  34. Nirsevimab and Hospitalization for Lower Respiratory Tract Infection During the Second Season · David Moreno‐Pérez · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)